Cabozantinib for Hepatocellular Carcinoma in Real-World Practice (CLERANCE): A Prospective, Interventional Study.

Date publication

novembre 2025

Journal

Liver cancer

Auteurs

Membres identifiés du Cancéropôle Est :
Pr BRONOWICKI Jean-Pierre

Tous les auteurs :
Villeret F, Bouattour M, Blanc JF, Péron JM, Debette-Gratien M, Nahon P, Nguyen Khac E, Phelip JM, Assenat E, Bourgeois V, Richou C, Heurgue A, Bronowicki JP, Ollivier-Hourmand I, Uguen T, Cattan S, Thevenon S, Boucheny C, Guilloreau P, Pradat P, Merle P

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/41394773

Résumé

Cabozantinib is recommended after sorafenib failure in systemic therapy of hepatocellular carcinoma (HCC), based on the results of CELESTIAL. Herein, CLERANCE was designed to evaluate the safety and efficacy of cabozantinib after prior sorafenib failure in real-life setting.

Mots clés

Cabozantinib, Hepatocellular carcinoma, Interventional study, Prospective, Real-world evidence, Systemic therapy

Référence

Liver Cancer. 2025 11 17;: